What are the key components of the executive compensation discussed in this filing?

This filing details the 2012 bonus awards, 2013 base salaries, and 2013 equity awards (stock options and performance share awards) granted to Gilead's named executive officers. The equity awards are designed with specific performance and service vesting conditions.

How are the performance share awards structured and what metrics are they tied to?

There are two main types of performance share awards. The TSR Performance Share Award is linked to Gilead's total shareholder return relative to peer companies in the S&P Healthcare Index over a three-year period. The Revenue Performance Share Award is tied to achieving specific consolidated revenue targets for the fiscal years 2013, 2014, and 2015.

What is the potential upside and downside for the executive officers based on these performance share awards?

The performance share awards can result in the conversion of performance shares into actual company stock at a rate of 0% to 200% of the target number, depending on the achievement of the performance goals. However, if the company's absolute TSR is negative, the TSR Performance Share Award payout is capped at 100% of the allocated shares. Performance shares are generally forfeited if an executive leaves the company before meeting service requirements, though exceptions exist for death, disability, or retirement.

What is the exercise price and vesting schedule for the stock options granted?

The stock options were granted with an exercise price of $40.56 per share, which was the closing price of Gilead's common stock on February 1, 2013. These options vest over a period of approximately three years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal quarterly installments thereafter, subject to continued employment.

GILD 8-K: Leadership Changes

Summary

This 8-K filing from Gilead Sciences, Inc. (GILD) on February 4, 2013, primarily details the compensation decisions made by the Compensation Committee for its named executive officers. Key decisions include the determination of 2012 bonus awards and the setting of 2013 base salaries. Additionally, the company has granted significant equity awards to its executive team, consisting of stock options and performance share awards, designed to incentivize future performance and align executive interests with shareholder value creation. The performance share awards are structured with both performance-vesting and service-vesting requirements, tied to critical company metrics such as total shareholder return (TSR) relative to specific healthcare industry benchmarks and revenue growth targets over multi-year periods. This compensation structure aims to reward executives for achieving substantial improvements in market performance and financial results, reflecting a forward-looking approach to executive compensation.

Key Highlights

12012 Bonus Awards and 2013 Base Salaries Set: The Compensation Committee finalized 2012 bonuses and established 2013 base salaries for key executive officers, including CEO John C. Martin.
2Significant 2013 Equity Awards Granted: Executive officers received substantial grants of stock options and performance share awards.
3Stock Options Granted with $40.56 Exercise Price: Options were granted with an exercise price equal to the closing stock price on February 1, 2013, vesting over three years.
4Performance Share Awards Tied to TSR and Revenue: Two types of performance share awards were granted: one based on total shareholder return (TSR) against S&P Healthcare Index subsets, and another linked to achieving specific revenue targets over 2013-2015.
5Performance Share Awards Offer Upside Potential: Awards can convert into shares at 0% to 200% of the target amount based on performance, with limits based on absolute TSR and executive tenure.
6Clawback Provisions and Vesting Adjustments: Provisions exist for forfeiture of awards upon termination, with pro-rata vesting in cases of retirement, death, or disability, and special terms for change in control.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Feb 5, 2013)

Summary

Key Highlights

Frequently Asked Questions